[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100447805":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":10,"centralContacts":34,"locations":40,"responsibleParty":64,"collaborators":66,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":10,"enrollmentInfo":78,"targetDuration":10,"studyType":81,"phases":10,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":43,"whyStopped":10,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Institut Pasteur","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Gp 1: 10 patients with cutaneous psoriasis",null,"Visits for research are done as part of the care, no visits are added. There is only 1 visit for patients of this group, they will be sampled once with 51 mL of blood before initiation of a biotherapy and some data will be collected",[13,14],"Other: Blood sample","Other: Data collection",{"label":16,"type":10,"description":17,"interventionNames":18},"Gp 2: 80 patients with a medical decision to treat cutaneous psoriasis with an anti-IL-23 biologic","Visits for research are done as part of the care, no visits are added. Two visits are planned for this group of patients : before and after initiation of therapy. These patients will be sampled twice with 51 mL of blood. Skin biopsies will be obtained from a subset of 30 patients to analyse the skin transcriptome, before and after treatment with anti-IL-23 biologics Data will be collected at the two timepoints.",[13,14,19],"Other: skin biopsies",[21,26,30],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":10},"OTHER","Blood sample","Blood will be collected in tubes heparinés BD (Vacutainer), homogenised, and immediately transported at room temperature to Institut Pasteur to be further processed",[9,16],{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":10},"Data collection","collection of socio-demographic, clinical and biological data.",[9,16],{"type":22,"name":31,"description":32,"armGroupLabels":33,"otherNames":10},"skin biopsies","skin biopsies of 4 mm in diameter. These samples will not be taken on the face or in an area of skin folds",[16],[35],{"name":36,"role":37,"phone":38,"phoneExt":10,"email":39},"Lars Rogge","CONTACT","+33140613822","lars.rogge@pasteur.fr",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Lars ROGGE","RECRUITING","Paris","Île-de-France Region","75015","France","FR",{"type":50,"coordinates":51},"Point",[52,53],2.3488,48.85341,{"lat":53,"lon":52},[56,60],{"name":57,"role":37,"phone":58,"phoneExt":10,"email":59},"Selim Aractangi, Pr","+33 1 58 41 18 13","selim.aractingi@aphp.fr",{"name":61,"role":37,"phone":62,"phoneExt":10,"email":63},"Benedicte Oules, Dr","+33 1 58 41 17 81","benedicte.oules@aphp.fr",{"type":65,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[67],{"name":68,"class":6},"Janssen Biotech, Inc.","100447805","exploration-of-the-cellular-and-molecular-mechanisms-in-patients-receiving-biotherapies-targeting-the-il-23il-17-axis-in-cutaneous-psoriasis-100447805",false,"NCT05111210","Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23\u002FIL-17 Axis in Cutaneous Psoriasis","Pso23","Inclusion Criteria:\n\nAll patients:\n\n* Adults (\\>18 years)\n* Presenting with cutaneous psoriasis\n* Patients have signed an informed consent\n* Beneficiary of the health insurance, except for the AME Only for patients of Group 1\n* Patients require systemic treatment for psoriasis\n* Patients are naïve to biological therapies\n\nOnly for patients of Group 2:\n\n* Patients requiring treatment with anti-IL-23 biologics (guselkumab, risankizumab, tildrakizumab) upon referent physician's decision.\n* Patients are naïve to biological therapies or have received only one biologic, with a \"wash-out\" period of at least 4 months\n\nNon inclusion Criteria:\n\nFor all :\n\n* Patient is minor\n* Patient is pregnant or breastfeeding\n* Patient is immunocompromised\n* Patient is under legal protection, curatorship, guardianship\n* Patient refuses consent\n* Patient is unable to comply with study requirements for geographic, social or psychiatric reason.\n* Beneficiary of the AME Only for patients of Group 1\n* Patient has received biologics Only for patients of Group 2\n* Patient has a contraindication to the chosen biotherapy\n* Patient has received biologics within the last 4 months\n* Patient has been treated with 2 or more biologics\n* Patient has already received an anti-IL-23 biologic","ALL","18 Years",{"count":79,"type":80},90,"ESTIMATED","OBSERVATIONAL","This is a research study involving humans, of the interventional type with minimal risks and constraints (RIPH2). It is a monocentric, non randomized prospective study aiming to better understand the mechanisms of the response to anti-IL-23 biologics in psoriasis patients attending the dermatology department of hospital Cochin (APHP).",[84],"Psoriasis",[86,87,88],"psoriasis","anti-IL-23 therapy","immune responses","2025-05-13",{"date":91,"type":92},"2025-05-14","ACTUAL",{"date":94,"type":92},"2021-12-14",{"date":96,"type":80},"2028-06-30",{"name":5,"class":6},1]